Evidence map›Paper›PMID 42868715›Full record

ArticleTranslational oncology2026

Machine learning and multi-omics analyses reveal CLDN1 as a candidate marker associated with colorectal cancer invasion and nutlin-3a (-) response.

Wenqi Shan, Qianyu Li, Wei Yuan, Ruiting Feng, Peiyao Hu, Zongmian Song, Yanfeng Li, Chenghan Luo, Ningjing Lei, Haozhe Zhang and 1 more

Abstract read
In one paragraph

Article in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Wenqi ShanThe Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China.
Qianyu LiThe Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China.
Wei YuanDepartment of Oncology, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China.
Ruiting FengTranslational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China.
Peiyao HuScientific Research Management Office, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China.
Zongmian SongDepartment of Orthopaedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Yanfeng LiTranslational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China.
Chenghan LuoDepartment of Orthopaedics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Ningjing LeiDepartment of Microbiology and Immunology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China. Electronic address: lnj717@zzu.edu.cn.
Haozhe ZhangTranslational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China. Electronic address: haozhe@hactcm.edu.cn.
Zhaorui WangTranslational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan, China. Electronic address: zhaorui1126@hactcm.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveColorectal cancer (CRC) is molecularly, cellularly and spatially heterogeneous, and current staging systems and biomarkers incompletely explain prognosis and treatment response. This study integrated transcriptomics, machine learning, single-cell RNA sequencing, spatial transcriptomics and in vitro experiments to prioritize candidate CRC-associated markers and characterize their potential biological and clinical relevance.

methodsGSE44861 and GSE44076 from the Gene Expression Omnibus (GEO) and The Cancer Genome Atlas Colon Adenocarcinoma (TCGA-COAD) were used for differential expression, consensus differentially expressed gene (DEG) identification and functional enrichment analyses. Four machine-learning algorithms were applied for feature selection. Candidate genes were prioritized by differential expression, model importance and receiver operating characteristic (ROC) performance. GSE231559 single-cell data and spatial transcriptomics characterized the cellular source, pseudotime dynamics and spatial distribution of the core gene. TCGA-COAD assessed prognosis, pathways and computationally predicted drug sensitivity. Western blotting, Transwell and MTT assays were used for experimental validation, and public immunohistochemistry images from the Human Protein Atlas were used as supplementary protein-expression evidence.

resultsWe identified 544 consensus DEGs enriched in leukocyte migration, chemotaxis, extracellular matrix organization, cytokine activity and metabolic pathways. Six genes were jointly selected: CLDN1, CDH3, KRT24, MMP7, NEBL and SCGN. CLDN1 was markedly upregulated and showed the highest tumour-versus-normal discrimination among the six candidates in the TCGA-COAD cohort. Single-cell and spatial analyses showed that CLDN1 was mainly expressed in CRC epithelial cells, displayed increasing expression across the inferred pseudotime ordering, and was enriched in malignant and mixed regions. In the TCGA-COAD cohort, high CLDN1 expression was associated with poorer overall survival and pathways involving the cell cycle, proteasome, autophagy, Hippo, ErbB and CRC. CLDN1 manipulation altered CRC-cell invasion and in vitro response to Nutlin-3a (-).

conclusionThese findings support CLDN1 as a candidate CRC-associated marker linked to malignant epithelial-cell states, tumour-associated spatial heterogeneity, invasive phenotype and Nutlin-3a (-) response. Further independent and prospective validation is required to determine its clinical diagnostic, prognostic and treatment-response relevance.

Indexed as

CLDN1Colorectal cancerMachine learningSingle-cell RNA sequencingSpatial transcriptomics

Identifiers

PMID42868715
PMCPMC13685891

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.